Kymera Therapeutics Inc Forecast, price target & analysts
Kymera Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Kymera Therapeutics Inc Classifications & Recommendation:
Kymera Therapeutics Inc Price Target
| Target Price | $60.08 |
| Price | $30.25 |
| Potential |
98.60%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Kymera Therapeutics Inc 2026 .
The average Kymera Therapeutics Inc target price is $60.08.
This is
98.60%
register free of charge
$97.00
220.66%
register free of charge
$51.00
68.60%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Kymera Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kymera Therapeutics Inc stock has an average upside potential 2026 of
98.60%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 78.59 | 53.87 |
| 67.82% | 31.45% | |
| EBITDA Margin | -206.09% | -440.03% |
| 39.02% | 113.51% | |
| Net Margin | -207.62% | -354.02% |
| 47.68% | 70.51% |
20 Analysts have issued a sales forecast Kymera Therapeutics Inc 2024 . The average Kymera Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2024. The average Kymera Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Kymera Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.52 | -2.95 |
| 12.20% | 17.06% | |
| P/E | negative | |
| EV/Sales | 33.94 |
7 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Kymera Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Kymera Therapeutics Inc...
Current Kymera Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Stephens & Co. | Locked ➜ Locked | Locked | Jan 21 2025 |
| Leerink Partners | Locked ➜ Locked | Locked | Dec 27 2024 |
| BTIG | Locked ➜ Locked | Locked | Dec 10 2024 |
| BMO Capital | Locked ➜ Locked | Locked | Dec 06 2024 |
| Wells Fargo | Locked ➜ Locked | Locked | Dec 02 2024 |
| Stephens & Co. | Locked ➜ Locked | Locked | Nov 18 2024 |
| Morgan Stanley | Locked ➜ Locked | Locked | Nov 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Stephens & Co.: Locked ➜ Locked
|
Jan 21 2025 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Dec 27 2024 |
|
Locked
BTIG: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
BMO Capital: Locked ➜ Locked
|
Dec 06 2024 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Dec 02 2024 |
|
Locked
Stephens & Co.: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Nov 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
